01 8Mucosta
02 8Mucosta Ophthalmic Suspension
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 72
2019 Revenue in Millions : 82
Growth (%) : -12
Main Therapeutic Indication : Ophthalmology
Currency : USD
2020 Revenue in Millions : 49
2019 Revenue in Millions : 50
Growth (%) : -2
Main Therapeutic Indication : Ophthalmology
Currency : USD
2021 Revenue in Millions : 46
2020 Revenue in Millions : 47
Growth (%) : 4
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 72
2020 Revenue in Millions : 69
Growth (%) : 12
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 78
2021 Revenue in Millions : 72
Growth (%) : 9
Main Therapeutic Indication : Ophthalmology
Currency : USD
2022 Revenue in Millions : 42
2021 Revenue in Millions : 46
Growth (%) : -9
Main Therapeutic Indication : Ophthalmology
Currency : USD
2023 Revenue in Millions : 29
2022 Revenue in Millions : 42
Growth (%) : -20
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2023 Revenue in Millions : 71
2022 Revenue in Millions : 78
Growth (%) : 3
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 117
2015 Revenue in Millions : 144
Growth (%) : -19
Main Therapeutic Indication : Ophthalmology
Currency : USD
2016 Revenue in Millions : 45
2015 Revenue in Millions : 45
Growth (%) : 0
LOOKING FOR A SUPPLIER?
